Skip to main content

Table 3 (abstract P294). See text for description

From: 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

 

mRCC

Groups based on therapies after IL-2

TT

TT & ICB

ICB

No TT or ICB

IL-2 first line (no prior or post therapy

n

190

14

12

196

149

mOS (months)

35.5

NR

NR

NR

NR

1-, 2-, 3-year survival (%)

81, 63, 49

100, 81, 81

90, 79, 79

76, 65, 65

82, 72, 72

Back to article page